Immune privilege or privileged immunity?

Mucosal Immunology

Volumn 1, Issue 5, 2008, Pages 372-381

  Forrester, J V ^a   Xu, H ^a   Lambe, T ^b   Cornall, R ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; APRIL PROTEIN; ARGINASE; AUTOANTIGEN; AUTOIMMUNE REGULATOR PROTEIN; CD200 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR4; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; GLYCINE; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERPHOTORECEPTOR RETINOID BINDING PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOCORTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PERFORIN; PROSTAGLANDIN E2; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA; STROMAL CELL DERIVED FACTOR 1; SUBSTANCE P; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TYROSINASE RELATED PROTEIN 2;

ADAPTIVE IMMUNITY; ALLOGRAFT; ALOPECIA AREATA; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; APOPTOSIS; AUTOIMMUNITY; BLOOD BRAIN BARRIER; BLOOD EYE BARRIER; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL KILLING; CYTOKINE RELEASE; FETOPLACENTAL UNIT; GRAFT REJECTION; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS; HISTOCOMPATIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; LEISHMANIA; LYMPHOID TISSUE; MUCOSAL IMMUNITY; NONHUMAN; ORGAN TRANSPLANTATION; PHOTORECEPTOR; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; REVIEW; SKIN; SKIN LEISHMANIASIS; TH2 CELL; TISSUE TYPES; TUMOR IMMUNITY; UVEORETINITIS;

EID: 50149115789     PISSN: 19330219     EISSN: None     Source Type: Journal    
DOI: 10.1038/mi.2008.27     Document Type: Review

References (120)

1. Niederkorn, J.Y. See no evil, hear no evil, do no evil: The lessons of immune privilege. Nat. Immunol. 7, 354-359 (2006).
2. Streilein, J.W. Ocular immune privilege: The eye takes a dim but practical view of immunity and inflammation. J. Leukoc. Biol. 74, 179-185 (2003).
3. Galea, I., Bechmann, I. & Perry, V.H. What is immune privilege (not)? Trends Immunol. 28, 12-18 (2007).
4. Wenkel, H., Streilein, J.W. & Young, M.J. Systemic immune deviation in the brain that does not depend on the integrity of the blood-brain barrier. J. Immunol. 164, 5125-5131 (2000).
5. Niederkorn, J.Y. The induction of anterior chamber-associated immune deviation. Chem. Immunol. Allergy 92, 27-35 (2007).
6. Waldmann, H., Adams, E., Fairchild, P. & Cobbold, S. Infectious tolerance and the long-term acceptance of transplanted tissue Immunol. Rev. 212, 301-313 (2006).
7. Cobbold, S.P. et al. Immune privilege induced by regulatory T cells in transplantation tolerance. Immunol. Rev. 213, 239-255 (2006).
8. Hunt, J.S. Stranger in a strange land. Immunol. Rev. 213, 36-47 (2006).
9. Niederkorn, J.Y. & Wang, S. Immune privilege of the eye and fetus: parallel universes? Transplantation 80, 1139-1444 (2005).
10. Kanellopoulos-Langevin, C., Caucheteux, S.M., Verbeke, P. & Ojcius, D.M. Tolerance of the fetus by the maternal immune system: Role of inflammatory mediators at the feto-maternal interface. Reprod. Biol. Endocrinol. 1, 121 (2003).
11. Weetman, A.P. The immunology of pregnancy. Thyroid 9, 643-646 (1999).
12. Mellor, A.L. & Munn, D.H. Creating immune privilege: Active local suppression that benefits friends, but protects foes. Nat. Rev. 8, 74-80 (2008).
13. Caspi, R.R. Ocular autoimmunity: The price of privilege? Immunol. Rev. 213, 23-35 (2006).
14. Medawar, P.B. Immunological tolerance. Nature 189, 14-17 (1961).
15. Bechmann, I., Galea, I. & Perry, V.H. What is the blood-brain barrier (not)? Trends Immunol. 28, 5-11 (2007).
16. Matter, K. & Balda, M.S. Holey barrier: Claudins and the regulation of brain endothelial permeability. J. Cell Biol. 161, 459-460 (2003).
17. Chan, W.Y., Kohsaka, S. & Rezaie, P. The origin and cell lineage of microglia: New concepts. Brain Res. Rev. 53, 344-354 (2007).
18. Xu, H., Chen, M., Mayer, E.J., Forrester, J.V. & Dick, A.D. Turnover of resident retinal microglia in the normal adult mouse. Glia 55 1189-1198 (2007).
19. Flugel, A. et al. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity 14, 547-560 (2001).
20. Xu, H., Manivannan, A., Liversidge, J., Sharp, P.F., Forrester, J.V. & Crane, I,J. Requirements for passage of T lymphocytes across non-inflamed retinal microvessels. J. Neuroimmunol. 142, 47-57 (2003).
21. Xu, H., Forrester, J.V., Liversidge, J. & Crane, I.J. Leukocyte trafficking in experimental autoimmune uveitis: Breakdown of blood-retinal barrier and upregulation of cellular adhesion molecules. Invest, Ophthalmol. Vis. Sci. 44, 226-234 (2003).
22. Xu, H., Manivannan, A., Crane, I.J., Dawson, R. & Liversidge, J. Critical but divergent roles for CD62L and CD44 in directing blood monocyte trafficking in vivo during inflammation. Blood (2008).
23. Xu, H. et al. Differentiation to the CCR2+ inflammatory phenotype in vivo is a constitutive, time-limited property of blood monocytes and is independent of local inflammatory mediators. J. Immunol. 175, 6915-6923 (2005).
24. Cserr, H.F & Knopf, P.M. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: A new view. Immunol. Today 13, 507-512 (1992).
25. McMenamin, P.G. Dendritic cells and macrophages in the uveal tract of the normal mouse eye. Br. J. Ophthalmol. 83, 598-604 (1999).
26. Forrester, J.V., McMenamin, P.G., Liversidge, J. & Lumsden, L. Dendritic cells and "dendritic" macrophages in the uveal tract. Adv. Exp. Med. Biol. 329, 599-604 (1993).
27. Plskova, J., Holan, V., Filipec, M. & Forrester, J.V. Lymph node removal enhances corneal graft survival in mice at high risk of rejection. BMC Ophthalmol. 4, 3 (2004).
28. Plskova, J., Duncan, L., Holan, V., Filipec, M., Kraal, G. & Forrester, J.V. The immune response to corneal allograft requires a site-specific draining lymph node. Transplantation 73, 210-215 (2002).
29. Dietrich, T. et al. Inhibition of inflammatory lymphangiogenesis by integrin alpha5 blockade. Am. J. Pathol. 171, 361-372 (2007).
30. Xu, H., Chen, M., Reid, D.M. & Forrester, J.V. LYVE-1-positive macrophages are present in normal murine eyes. Invest. Ophthalmol. Vis. Sci. 48, 2162-2171 (2007).
31. Fijak, M. & Meinhardt, A. The testis in immune privilege. Immunol. Rev. 213, 66-81 (2006).
32. Crispe, I.N., Giannandrea, M., Klein, I., John, B., Sampson, B. & Wuensch, S. Cellular and molecular mechanisms of liver tolerance. Immunol. Rev. 213, 101-118 (2006).
33. Paus, R., Ito, N., Takigawa, M. & Ito, T. The hair follicle and immune privilege. J. Investig. Dermatol. Symp. Proc. 8, 188-194 (2003).
34. Hickey, D.K. et al. Intranasal immunization with C. muridarum major outer membrane protein (MOMP) and cholera toxin elicits local production of neutralising IgA in the prostate. Vaccine 22, 4306-4315 (2004). 35 Knop, E. & Knop, N. Anatomy and immunology of the ocular surface. Chem. Immunol. Allergy 92, 36-49 (2007).
35. Iweala, O.I. & Nagler, C.R. Immune privilege in the gut: The establishment and maintenance of non-responsiveness to dietary antigens and commensal flora. Immunol. Rev. 213, 82-100 (2006).
36. Benson, J.L. & Niederkorn, J.Y. In situ suppression of delayed-type hypersensitivity: Another mechanism for sustaining the immune privilege of the anterior chamber. Immunology 74, 153-159 (1991).
37. Medawar, P.B. Immunity to homologous grafted skin. Br. J. Exp. Pathol. 29, 58-69 (1948).
38. Copland, D.A. et al. Monoclonal antibody-mediated CD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis. Am. J. Pathol. 171, 580-588 (2007).
39. Askenasy, N., Yolcu, E.S., Yaniv, I. & Shirwan, H. Induction of tolerance using Fas ligand: A double-edged immunomodulator. Blood 105, 1396-1404 (2005).
40. Dick, A.D. et al. Fas-Fas ligand -mediated apoptosis within aqueous during idiopathic acute anterior uveitis. Invest. Ophthalmol. Vis. Sci., 40, 2258-2267 (1999).
41. Ferguson, T.A. & Griffith, T.S. A vision of cell death: Insights into immune privilege. Immunol. Rev. 156, 167-184 (1997).
42. Ferguson, T.A. & Griffith, T.S. A vision of cell death: Fas ligand and immune privilege 10 years later. Immunol. Rev. 213, 228-238 (2006).
43. Ferguson, T.A. & Griffith, T.S. The role of Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) in the ocular immune response. Chem. Immunol. Allergy 92, 140-154 (2007).
44. Phillips, T.A. et al. TRAIL (Apo-2L) and TRAIL receptors in human placentas: Implications for immune privilege. J. Immunol. 162 6053-6059 (1999).
45. Wosik, K., Biernacki, K., Khouzam, M.P. & Prat, A. Death receptor expression and function at the human blood brain barrier. J. Neurol. Sci. 259, 53-60 (2007).
46. Gregory, M.S. et al. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege. Invest. Ophthalmol. Vis. Sci. 46, 2495-2502 (2005).
47. Gregory, M.S., Repp, A.C., Holhbaum, A.M., Saff, R.R., Marshak-Rothstein, A. & Ksander, B.R. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege. J. Immunol. 169, 2727-2735 (2002).
48. Griffith, T.S., Brunner, T., Fletcher, S.M., Green, D.R. & Ferguson, T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189-1192 (1995).
49. Head, J.R., Neaves, W.B. & Billingham, R.E. Reconsideration of the lymphatic drainage of the rat testis. Transplantation 35, 91-95 (1983).
50. Ferguson, T.A., Green, D.R. & Griffith, T.S. Cell death and immune privilege. Int. Rev. Immunol. 21, 153-172 (2002).
51. Koyama, S. Apoptotic depletion of infiltrating mucosal lymphocytes associated with Fas ligand expression by Helicobacter pylori-infected gastric mucosal epithelium: Human glandular stomach as a site of immune privilege. Dig. Dis. Sci. 45, 773-780 (2000).
52. Cousins, S.W., Trattler, W.B. & Streilein, J.W. Immune privilege and suppression of immunogenic inflammation in the anterior chamber of the eye. Curr. Eye Res. 10, 287-297 (1991).
53. Gormley, P.D., Powell-Richards, A.O., Azuara-Blanco, A., Donoso, L.A. & Dua, H.S. Lymphocyte subsets in conjunctival mucosa-associated-lymphoid-tissue after exposure to retinal-S-antigen. Int. Ophthalmol. 22, 77-80 (1998).
54. Sugerman, P.B. et al. The pathogenesis of oral lichen planus. Crit. Rev. Oral. Biol. Med. 13, 350-365 (2002).
55. Geerts, A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin. Liver Dis. 21, 311-335 (2001).
56. Khanna, A., Morelli, A.E., Zhong, C., Takayama, T., Lu, L. & Thomson, A.W. Effects of liver-derived dendritic cell progenitors on Th1- and Th2-like cytokine responses in vitro and in vivo. J. Immunol. 164, 1346-1354 (2000).
57. Westgate, G.E., Craggs, R.I. & Gibson, W.T. Immune privilege in hair growth. J. Invest. Dermatol. 97, 417-420 (1991).
58. Ito, T. et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J. Invest. Dermatol. 128, 1196-1206 (2008).
59. Ito, T., Ito, N., Bettermann, A., Tokura, Y., Takigawa, M. & Paus, R. Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle ass model. Am. J. Pathol. 164, 623-634 (2004).
60. Christoph, T. et al. The human hair follicle immune system: cellular composition and immune privilege. Br. J. Dermatol. 142 862-873 (2000).
61. Alvarez, D., Arkinson, J.L., Sun, J., Fattouh, R., Walker, T. & Jordana, M. Th2 differentiation in distinct lymph nodes influences the site of mucosal Th2 immune-inflammatory responses. J. Immunol. 179, 3287-3296 (2007).
62. Wilbanks. G.A. & Streilein, J.W. Studies on the induction of anterior chamber-associated immune deviation (ACAID). 1. Evidence that an antigen-specific, ACAID-inducing, cell-associated signal exists in the peripheral blood. J. Immunol. 146, 2610-2617 (1991).
63. Wilbanks, G.A., Mammolenti, M. & Streilein, J.W. Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-beta. Eur. J. Immunol. 22, 165-173 (1992).
64. Takahashi, M. et al. Requirement for splenic CD4+ T cells in the immune privilege of the anterior chamber of the eye. Clin. Exp. Immunol. 116, 231-237 (1999).
65. Stein-Streilein, J. & Watte, C. Cross talk among cells promoting anterior chamber-associated immune deviation. Chem. Immunol. Allergy 92, 115-130 (2007).
66. Sonoda, K.H. & Stein-Streilein, J. Ocular immune privilege and CD1d-reactive natural killer T cells. Cornea 21, S33-38 (2002).
67. Skelsey, M.E., Mellon, J. & Niederkorn, J.Y. Gamma delta T cells are needed for ocular immune privilege and corneal graft survival, J. Immunol. 166, 4327-4333 (2001).
68. Niederkorn, J.Y. & Mayhew, E. Role of splenic B cells in the immune privilege of the anterior chamber of the eye. Eur. J. Immunol. 25, 2783-2787 (1995).
69. Guller, S. Role of Fas ligand in conferring immune privilege to non-lymphoid cells. Ann. N. Y. Acad. Sci. 828, 268-272 (1997).
70. Arcuri, F. et al. Human decidual natural killer cells as a source and target of macrophage migration inhibitory factor. Reproduction 131, 175-182 (2006).
71. Menier, C., Riteau, B., Dausset, J., Carosella, E.D. & Rouas-Freiss, N. HLA-G truncated isoforms can substitute for HLA-G1 in fetal survival. Hum. Immunol. 61, 1118-1125 (2000).
72. Hunt, J.S., Langat, D.K., McIntire, R.H. & Morales, P.J. The role of HLA-G in human pregnancy. Reprod. Biol. Endocrinol. 4 (Suppl 1), S10 (2006).
73. Katz, J.B., Muller, A.J. & Prendergast, G.C. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol. Rev. 222, 206-221 (2008).
74. Cabestre, F.A. et al. HLA-G expression: Immune privilege for tumour cells? Semin. Cancer Biol. 9, 27-36 (1999).
75. Linkermann, A., Qian, J., Lettau, M., Kabelitz, D. & Janssen, O. Considering I-as ligand as a target for therapy. Expert Opin. Ther. Targets 9, 119-134 (2005).
76. Minas, V. et al. Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation. Br. J. Cancer 97 637-645 (2007).
77. Curiel, T.J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942-949 (2004).
78. Juszczynski, P. et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc. Natl Acad. Sci. USA 104, 13134-13139 (2007).
79. Wahl, S.M., Wen, J. & Moutsopoulos, N. TGF-beta: A mobile purveyor of immune privilege. Immunol. Rev. 213, 213-227 (2006).
80. Munn, D.H. & Mellor, A.L. The tumor-draining lymph node as an immune-privileged site. Immunol. Rev. 213, 146-158 (2006).
81. Ishida, T. et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res. 66, 5716-5722 (2006).
82. Peters, N. & Sacks, D. Immune privilege in sites of chronic infection: Leishmania and regulatory T cells. Immunol. Rev. 213, 159-179 (2006).
83. Lepisto, A.J., Frank, G.M. & Hendricks, R.L. How herpes simplex virus type 1 rescinds corneal privilege. Chem. Immunol. Allergy 92 203-212 (2007).
84. Persidsky, Y. & Poluektova, L. Immune privilege and HIV-1 persistence in the CNS. Immunol. Rev. 213, 180-194 (2006).
85. Singh, N.J. & Schwartz, R.H. Primer: Mechanisms of immunologic tolerance. Nat. Clin. Pract. 2, 44-52 (2006).
86. Anderson, M.S., Venanzi, E.S., Chen, Z., Berzins, S.P., Benoist, C. & Mathis, D. The cellular mechanism of Aire control of T cell tolerance. Immunity 23, 227-239 (2005).
87. Ferguson, B.J., et al. AIRE's CARD revealed, a new structure for central tolerance provokes transcriptional plasticity. J. Biol. Chem. 283, 1723-1731 (2008).
88. Egwuagu, C.E., Charukamnoetkanok, P. & Gery, I. Thymic expression of autoantigens correlates with resistance to autoimmune disease. J. Immunol. 159, 3109-3112 (1997).
89. DeVoss, J. et al. Spontaneous autoimmunity prevented by thymic. expression of a single self-antigen. J. Exp. Med. 203, 2727-2735 (2006).
90. Caspi, R.R. Immunopathology of the eye. Semin. Immunopathol. 30 63-64 (2008).
91. Caspi, R.R. et al. Mouse models of experimental autoimmune uveitis. Ophthalmic. Res. 40, 169-174 (2008).
92. Lambe, T. et al. CD4T cell-dependent autoimmunity against a melanocyte neoantigen induces spontaneous vitiligo and depends upon Fas-Fas ligand interactions. J. Immunol. 177, 3055-3062 (2006).
93. Lambe, T. et al. Limited peripheral T cell anergy predisposes to retinal autoimmunity. J. Immunol. 178, 4276-4283 (2007).
94. Sosnova, M., Bradl, M. & Forrester, J.V. CD34+ corneal stromal cells are bone marrow-derived and express hemopoietic stem cell markers. Stem Cells 23, 507-515 (2005).
95. McMenamin, P.G., Holthouse, I. & Holt, P.G. Class II major histocompatibility complex (Ia) antigen-bearing dendritic cells within the iris and ciliary body of the rat eye: Distribution, phenotype and relation to retinal microglia. Immunology 77, 385-393 (1992).
96. McMenamin, P.G. Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations. J. Comp. Neurol. 405, 553-562 (1999).
97. Xu, H., Dawson, R., Forrester, J.V. & Liversidge, J. Identification of novel dendritic cell populations in normal mouse retina. Invest. Ophthalmol. Vis. Sci. 48, 1701-1710 (2007).
98. Dudziak, D. et al. Differential antigen processing by dendritic cell subsets in vivo. Science 315, 107-111 (2007).
99. Nussenzweig, M.C., Steinman, R.M., Witmer, M.D. & Gutchinov, B. A monoclonal antibody specific for mouse dendritic cells. Proc. Natl Acad. Sci. USA 79, 161-165 (1982).
100. Hill, M., Zagani, R., Voisine, C., Usal, C. & Anegon, I. Nitric oxide and indoleamine 2,3-dioxygenase mediate CTLA4Ig-induced survival in heart allografts in rats. Transplantation 84, 1060-1063 (2007).
101. Rossner, S., Voigtlander, C., Wiethe, C., Hanig, J., Seifarth, C. & Lutz, M.B. Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur. J. Immunol. 35, 3533-3544 (2005).
102. Yamada, J. & Streilein, J.W. Fate of orthotopic corneal allografts in C57BL/6 mice. Transpl. Immunol. 6, 161-168 (1998).
103. Zhang-Hoover, J. & Stein-Streilein, J. Therapies based on principles of ocular immune privilege. Chem. Immunol. Allergy 92, 317-327 (2007).
104. Katagiri, K., Zhang-Hoover, J., Mo, J.S., Stein-Streilein, J. & Streilein, J.W. Using tolerance induced via the anterior chamber of the eye to inhibit Th2-dependent pulmonary pathology. J. Immunol. 169, 84-89 (2002).
105. Forrester, J.V. Intermediate and posterior uveitis. Chem. Immunol. Allergy 92, 228-243 (2007).
106. Daley, S.R., Ma, J., Adams, E., Cobbold, S.P. & Waldmann, H. A key role for TGF-beta signaling to T cells in the long-term acceptance of allografts. J. Immunol. 179, 3648-3654 (2007).
107. Yates, S.F. et al. Induction of regulatory T cells and dominant tolerance by dendritic cells incapable of full activation. J. Immunol. 179, 967-976 (2007).
108. Mitchison, N.A., Katz, D.R. & Chain, B. Self/nonself discrimination among immunoregulatory (CD4) T cells. Semin. Immunol. 12, 179-183; discussion 257-344 (2000).
109. Matzinger, P. The danger model: A renewed sense of self: Science 296, 301-305 (2002).
110. Janeway, C.A. Jr. & Medzhitov, R. Innate immune recognition. Annu. Rev. Immunol. 20, 197-216 (2002).
111. Simpson, E. A historical perspective on immunological privilege. Immunol. Rev. 213, 12-22 (2006).
112. Matzinger, P. An innate sense of danger. Ann. N. Y. Acad. Sci. 961, 341-342 (2002).
113. Head, J.R. & Billingham, R.E. Immune privilege in the testis. II. Evaluation of potential local factors. Transplantation 40, 269-275 (1985).
114. Head, J.R., Neaves, W.B. & Billingham, R.E. Immune privilege in the testis. I. Basic parameters of allograft survival. Transplantation 36, 423-431 (1983).
115. Kersh, G.J. Transcriptional control of thymocyte positive selection. Immunol. Res. 29, 125-138 (2004).
116. Matsumoto, M. Transcriptional regulation in thymic epithelial cells for the establishment of self tolerance. Arch. Immunol. Ther. Exp. 55, 27-34 (2007).
117. Hollander, G., Gill, J., Zuklys, S., Iwanami, N., Liu, C. & Takahama, Y. Cellular and molecular events during early thymus development. Immunol. Rev. 209, 28-46 (2006).
118. de Boer, O.J., van der Loos, C.M., Teeling, P., van der Wal, A.C. & Teunissen, M.B. Immunohistochemical analysis of regulatory T cell markers FOXP3 and GITR on CD4+0025+ T cells in normal skin and inflammatory dermatoses. J. Histochem. Cytochem. 55, 891-898 (2007).
119. Matzinger, P. Friendly and dangerous signals: Is the tissue in control? Nat. Immunol. 8, 11-13 (2007).
120. Kyewski, B. & Klein, L. A central role for central tolerance. Ann. Rev. Immunol. 24, 571-606 (2006).